VEGFR2/KDR Protein, Mouse, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 110 kDa and the accession number is P35918.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
100 μg | ¥ 3,820 | 5日内发货 | ||
1 mg | ¥ 24,900 | 5日内发货 |
生物活性 | Immobilized mouse VEGF164 at 10 μg/ml (100 μl/well) can bind mouse KDR-Fc, The EC50 of mouse KDR-Fc is 0.11-0.27 μg/ml. |
产品描述 | VEGFR2/KDR Protein, Mouse, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 110 kDa and the accession number is P35918. |
种属 | Mouse |
表达系统 | HEK293 Cells |
标签 | C-hFc |
蛋白编号 | P35918 |
别名 | VEGFR2, 6130401C07, Krd-1, kinase insert domain receptor, Flk-1, VEGFR-2, Ly73, Flk1, sVEGFR-2 |
蛋白构建 | The Mouse KDR (P35918) (Met1-Glu762) was expressed, fused with the Fc region of Human IgG1 at the C-terminus. |
蛋白纯度 | > 90 % as determined by SDS-PAGE |
分子量 | 110 kDa (predicted) |
内毒素 | < 1.0 EU/μg of the protein as determined by the LAL method. |
缓冲液 | Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization. |
复溶方法 | A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information. |
存储 |
It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at-80℃. For reconstituted proteinsolutions, the solution can be stored at -20°c to -80'c for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
运输方式 |
In general, Lyophilized powders are shipping with blue ice. |
研究背景 | VEGFR2 also called KDR or Flk-1, is identified as the receptor for VEGF and VEGFC and an early marker for endothelial cell progenitors, whose expression is restricted to endothelial cells in vivo. VEGFR2 was shown to be the primary signal transducer for angiogenesis and the development of pathological conditions such as cancer and diabetic retinopathy. It has been shown that VEGFR2 is expressed mainly in the endothelial cells, and the expression is upregulated in the tumor vasculature. Thus the inhibition of VEGFR2 activity and its downstream signaling are important targets for the treatment of diseases involving angiogenesis. VEGFR2 transduces the major signals for angiogenesis via its strong tyrosine kinase activity. However, unlike other representative tyrosine kinase receptors, VEGFR2 does not use the Ras pathway as major downstream signaling but rather uses the phospholipase C-protein kinase C pathway to signal mitogen-activated protein (MAP)-kinase activation and DNA synthesis. VEGFR2 is a direct and major signal transducer for pathological angiogenesis, including cancer and diabetic retinopathy, in cooperation with many other signaling partners; thus, VEGFR2 and its downstream signaling appear to be critical targets for the suppression of these diseases. VEGF and VEGFR2-mediated survival signaling are critical to endothelial cell survival, maintenance of the vasculature and alveolar structure, and regeneration of lung tissue. Reduced VEGF and VEGFR2 expression in emphysematous lungs has been linked to increased endothelial cell death and vascular regression.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy |
bottom
您可能有的问题的答案可以在重组蛋白操作手册中找到
VEGFR2/KDR Protein, Mouse, Recombinant (hFc) VEGFR2 6130401C07 VEGFR 2 Krd-1 kinase insert domain receptor Flk-1 VEGFR-2 Ly73 Flk1 sVEGFR-2 recombinant recombinant-proteins proteins protein